Breaking Stigmas: A Black Father’s Experience in the Psychedelic Movement
By Kevin Cranford, Jr. M.S. MAPS Bulletin: Volume XXXIII Number 2 • 2023
The Psychedelic Superhighway
By Joseph McCowan, Psy.D. MAPS Bulletin: Volume XXXIII Number 1 • 2023
Criminal Legal System Reform for a Healthier Society
By Sia Henry, J.D. MAPS Bulletin: Volume XXXIII Number 1 • 2023
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
FOR IMMEDIATE RELEASE: January 16, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) reintroduces itsFiscal Sponsorship Program, signaling a new era of support for grassroots organizations …
MAPS Submits Cannabis Data Safety Update Report 2023 to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)
On January 11, 2024, MAPS submitted to the FDA the 2023 Cannabis Data Safety Update Report (DSUR). The DSUR serves as the FDA Annual Report on the progress of the drug investigation over the last year. …
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
FOR IMMEDIATE RELEASE: January 5, 2024 A decade after it was founded as a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation (MAPS …
FDA Continues Clinical Hold for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On December 28, 2023, the FDA Informed MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued. This Clinical Hold letter rejects the …
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
FOR IMMEDIATE RELEASE: December 13, 2023 MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from …
49ers’ Jon Feliciano supports MAPS as part of the 2023 NFL “My Cleats, My Cause” campaign
FOR IMMEDIATE RELEASE: December 4, 2023 Yesterday’s highly anticipated football game between the San Francisco 49ers and the Philadelphia Eagles brought additional excitement to the field thanks to 49ers’ …
MAPS Submits Complete Response to FDA’s Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
MAPS’ proposed Study MJP2 study is a research study that is intended to add to the cannabis safety literature and contribute to a better understanding of the safety and effectiveness of real-world …
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
FOR IMMEDIATE RELEASE: November 11, 2023 In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical …